Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18384636 | 0.95 | CASP6 (0.37) | CASP6NSD2HSP90AA1HSP90AB1PABPC1 | |
| SCHEMBL21237006 | 0.84 | CASP6 (0.39) | CASP6NSD2HSP90AA1HSP90AB1PABPC1 | |
| SCHEMBL21237001 | 0.81 | HSP90AA1 (0.35) | CASP6NSD2HSP90AA1HSP90AB1PABPC1 | |
| SCHEMBL18384665 | 0.78 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL18384670 | 0.78 | KDM4E (0.41) | CASP6NSD2PABPC1CASP7PDE4A | |
| SCHEMBL18384666 | 0.77 | KDM4E (0.44) | CASP6HSP90AA1PABPC1CASP7PDE4A | |
| SCHEMBL18384664 | 0.75 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL18384651 | 0.75 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL18384637 | 0.73 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL18384608 | 0.73 | HSP90AA1 (0.36) | CASP6NSD2HSP90AA1HSP90AB1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934309-B2 | Tricyclic quinone derivative | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-3127907-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | Boston Biomedical, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | CASP6 3962/4885NSD2 958/4885HSP90AA1 2704/4885 |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | CASP6 3962/4885NSD2 958/4885HSP90AA1 2704/4885 |
| US-10934309-B2 | Tricyclic quinone derivative | NQO1, NQO2, SQOR | CASP6 4211/4885NSD2 836/4885HSP90AA1 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.